CES4A

Across TCGA pan-cancer cohorts, CES4A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CES4A data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CES4A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CES4A expression acts as an unfavorable survival marker.

BLCA, COAD, and LUSC are the cancer types where CES4A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.252	0.723	<.001	33	view →
COAD	DFS	Median	All	0.140	0.783	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.270	0.744	.002	18	view →
PRAD	DFS	Median	All	0.234	0.781	.002	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CES4A–BLCA (OS)

Open the BLCA breakdown →